Methylation marks in blood DNA reveal breast cancer risk in patients fulfilling hereditary disease criteria
Less than 15–20% of patients who meet the criteria for hereditary breast and ovarian cancer (HBOC) carry pathogenic coding genetic mutations, implying that other molecular mechanisms may contribute to the increased risk of this condition. DNA methylation in peripheral blood has been suggested as a p...
Gespeichert in:
Veröffentlicht in: | NPJ precision oncology 2024-06, Vol.8 (1), p.136-13, Article 136 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Less than 15–20% of patients who meet the criteria for hereditary breast and ovarian cancer (HBOC) carry pathogenic coding genetic mutations, implying that other molecular mechanisms may contribute to the increased risk of this condition. DNA methylation in peripheral blood has been suggested as a potential epigenetic marker for the risk of breast cancer (BC). We aimed to discover methylation marks in peripheral blood associated with BC in 231 pre-treatment BC patients meeting HBOC criteria, testing negative for coding pathogenic variants, and 156 healthy controls, through methylation analysis by targeted bisulfite sequencing on 18 tumor suppressor gene promoters (330 CpG sites). We found i) hypermethylation in
EPCAM
(17 CpG sites;
p
= 0.017) and
RAD51C
(27 CpG sites;
p
= 0.048); ii) hypermethylation in 36 CpG-specific sites (FDR
q
|
---|---|
ISSN: | 2397-768X 2397-768X |
DOI: | 10.1038/s41698-024-00611-z |